FDA

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

News

For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

News

For Immediate Release: May 24, 2023 Today, the U.S. Food and Drug Administration (FDA) approved the extended-release Brixadi (buprenorphine) subcutaneous (for use under the skin) injection to treat moderate to severe opioid use disorder...

Some E-cigarette Users Are Having Seizures: Most Reports Involving Youth and Young Adults

News

Source: https://www.fda.gov/TobaccoProducts/NewsEvents/ucm635133.htm “The FDA has become aware that some people who use e-cigarettes have experienced seizures, with most reports involving youth or young adult users. Seizures or convulsions...

Eliminating Youth Electronic Cigarette Use: The Role for Drug Therapies Public Hearing

5 December 2018

Webcast

United States

The Food and Drug Administration (FDA or the Agency) is announcing a public hearing to discuss the effort to eliminate youth electronic cigarette (e-cigarette) use as well as other tobacco product use, with a focus on the potential role of drug therapies to support cessation and the issues impacting the development of such therapies.

Date and Location

December 5, 2018

The meeting will be held at:

Potential Public Health Effects of Reducing Nicotine Levels in Cigarettes in the United States

Scientific article

3 May 2018

Conclusions of this study indicate that enacting a regulation to lower the nicotine content of cigarettes to minimally addictive levels in the United States would lead to a substantial reduction in tobacco-related mortality, despite...